TLSA

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).

Wall Street analysts forecast TLSA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tiziana Life Sciences Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

Tiziana Life Sciences Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

Tiziana Life Sciences Ltd (TLSA) has 8 emplpoyees as of December 15 2025.

Today TLSA has the market capitalization of 211.51M USD.